171 related articles for article (PubMed ID: 36469316)
21. Practice and Impact of Multidisciplinary Tumor Boards on Patient Management: A Prospective Study.
Charara RN; Kreidieh FY; Farhat RA; Al-Feghali KA; Khoury KE; Haydar A; Nassar L; Berjawi G; Shamseddine A; El Saghir NS
J Glob Oncol; 2017 Jun; 3(3):242-249. PubMed ID: 28717766
[TBL] [Abstract][Full Text] [Related]
22. Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer.
Krause A; Stocker G; Gockel I; Seehofer D; Hoffmeister A; Bläker H; Denecke T; Kluge R; Lordick F; Knödler M
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1231-1240. PubMed ID: 35394231
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.
Rieke DT; Lamping M; Schuh M; Le Tourneau C; Basté N; Burkard ME; Metzeler KH; Leyvraz S; Keilholz U
JCO Precis Oncol; 2018 Nov; 2():1-14. PubMed ID: 35135153
[TBL] [Abstract][Full Text] [Related]
24. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic concordance among pathologists interpreting breast biopsy specimens.
Elmore JG; Longton GM; Carney PA; Geller BM; Onega T; Tosteson AN; Nelson HD; Pepe MS; Allison KH; Schnitt SJ; O'Malley FP; Weaver DL
JAMA; 2015 Mar; 313(11):1122-32. PubMed ID: 25781441
[TBL] [Abstract][Full Text] [Related]
26. Quality of leadership in multidisciplinary cancer tumor boards: development and evaluation of a leadership assessment instrument (ATLAS).
Jalil R; Soukup T; Akhter W; Sevdalis N; Green JSA
World J Urol; 2018 Jul; 36(7):1031-1038. PubMed ID: 29502300
[TBL] [Abstract][Full Text] [Related]
27. Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the
Elmore JG; Elder DE; Barnhill RL; Knezevich SR; Longton GM; Titus LJ; Weinstock MA; Pepe MS; Nelson HD; Reisch LM; Radick AC; Piepkorn MW
JAMA Netw Open; 2018 May; 1(1):. PubMed ID: 30556054
[TBL] [Abstract][Full Text] [Related]
28. Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Liu A; Vicenzi P; Sharma I; Orr K; Teller C; Koentz M; Trinkman H; Vallance K; Ray A
Hematol Rep; 2023 Apr; 15(2):244-255. PubMed ID: 37092519
[TBL] [Abstract][Full Text] [Related]
29. Molecular Tumor Boards: current practice and future needs.
van der Velden DL; van Herpen CML; van Laarhoven HWM; Smit EF; Groen HJM; Willems SM; Nederlof PM; Langenberg MHG; Cuppen E; Sleijfer S; Steeghs N; Voest EE
Ann Oncol; 2017 Dec; 28(12):3070-3075. PubMed ID: 29045504
[TBL] [Abstract][Full Text] [Related]
30. Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity.
Keikes L; Kos M; Verbeek XAAM; Van Vegchel T; Nagtegaal ID; Lahaye MJ; Méndez Romero A; De Bruijn S; Verheul HMW; Rütten H; Punt CJA; Tanis PJ; Van Oijen MGH
Int J Qual Health Care; 2021 Apr; 33(2):. PubMed ID: 33760073
[TBL] [Abstract][Full Text] [Related]
31. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
[TBL] [Abstract][Full Text] [Related]
32. Improving Outcomes of Witnessed Out-of-Hospital Cardiac Arrest After Implementation of International Liaison Committee on Resuscitation 2010 Consensus: A Nationwide Prospective Observational Population-Based Study.
Kaneko H; Hara M; Mizutani K; Yoshiyama M; Yokoi K; Kabata D; Shintani A; Kitamura T
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862948
[TBL] [Abstract][Full Text] [Related]
33. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).
Sunami K; Takahashi H; Tsuchihara K; Takeda M; Suzuki T; Naito Y; Sakai K; Dosaka-Akita H; Ishioka C; Kodera Y; Muto M; Wakai T; Yamazaki K; Yasui W; Bando H; Fujimoto Y; Fukuoka S; Harano K; Kawazoe A; Kimura G; Koganemaru S; Kogawa T; Kotani D; Kuboki Y; Matsumoto H; Matsumoto S; Mishima S; Nakamura Y; Sawada K; Shingaki S; Shitara K; Umemoto K; Umemura S; Yasuda K; Yoshino T; Yamamoto N; Nishio K; ; ;
Cancer Sci; 2018 Sep; 109(9):2980-2985. PubMed ID: 30187675
[TBL] [Abstract][Full Text] [Related]
34. AMBAR - Interactive Alteration annotations for molecular tumor boards.
Fürstberger A; Ikonomi N; Kestler AMR; Marienfeld R; Schwab JD; Kuhn P; Seufferlein T; Kestler HA
Comput Methods Programs Biomed; 2023 Oct; 240():107697. PubMed ID: 37441893
[TBL] [Abstract][Full Text] [Related]
35. Molecular tumour boards - current and future considerations for precision oncology.
Tsimberidou AM; Kahle M; Vo HH; Baysal MA; Johnson A; Meric-Bernstam F
Nat Rev Clin Oncol; 2023 Dec; 20(12):843-863. PubMed ID: 37845306
[TBL] [Abstract][Full Text] [Related]
36. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Rolfo C; Manca P; Salgado R; Van Dam P; Dendooven A; Ferri Gandia J; Rutten A; Lybaert W; Vermeij J; Gevaert T; Weyn C; Lefebure A; Metsu S; Van Laere S; Peeters M; Pauwels P; Machado Coelho A
ESMO Open; 2018; 3(5):e000398. PubMed ID: 30094075
[TBL] [Abstract][Full Text] [Related]
37. Quality Measures for Multidisciplinary Tumor Boards and Their Role in Improving Cancer Care.
Abuelgasim KA; Jazieh AR
Glob J Qual Saf Healthc; 2024 Feb; 7(1):28-33. PubMed ID: 38406654
[TBL] [Abstract][Full Text] [Related]
38. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
[TBL] [Abstract][Full Text] [Related]
39. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
40. Concordance Between Watson for Oncology and Multidisciplinary Teams in Colorectal Cancer: Prognostic Implications and Predicting Concordance.
Mao C; Yang X; Zhu C; Xu J; Yu Y; Shen X; Huang Y
Front Oncol; 2020; 10():595565. PubMed ID: 33425748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
